Comments
Dr Reddy’s Laboratories Ltd (DRL) has launched paricalcitol injection, a therapeutic equivalent generic version of Zemplar (paricalcitol) injection, in the US market. The vaccination is used in treatments associated with chronic kidney disease. The Zemplar brand had US sales of approximately $22.5 million for the most recent twelve months ending in July 2016 according to IMS Health. Zemplar is a registered trademark of ABBVIE Inc, according to a release. OUR BUREAU
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.